Quality of Life of Patients With Desmoid-type Fibromatosis

Status Completed

Clinical Trial Summary

Rationale: Desmoid-type fibromatosis (DTF) is a rare, histologically benign, soft tissue tumour. Although incapable of metastasizing, the clinical course is unpredictable and can be aggressive because of local invasive growth. Various treatments are available including; surgical resection, radiotherapy, hormonal therapy and chemotherapy. Nowadays there is a trend towards a more conservative strategy with a wait and see policy because of high recurrence rates after surgical resection. Health-related quality of life (HRQL) is a corner stone in treatment choice and can be used during the disease for monitoring the impact of the disease on physical, psychological and social level. Additionally, HRQL can be in important endpoint for future clinical trials. Today, no HRQL-tools are available which capture the needs of DTF patients. The hypothesis is that patients with DTF have issues on several HRQL domains including physical, social and emotional well-being. For this reason we developed a list of items based on previous research. This study aims to evaluate HRQL issues experienced by DTF patients. Purpose: Multi-centre, cross-sectional, observational study to measure HRQL of DTF patients and to evaluate the prevalence of the experienced problems.

Clinical Trial Description

Objectives: The primary objective is to evaluate HRQoL problems in adult DTF patients. The secondary objectives are: 1) to compare the level of HRQoL of DTF patients to the general population, 2) to identify patient subgroups who are at risk for developing certain HRQoL problems, 3) to evaluate patient preferences regarding their health care needs for DTF. Outline: All patients, aged above 18 years, with a histopathological proved DTF tumour and sufficient Dutch language skills who have received their last check-up in the hospital within the last five years (April 2014). Patients treated in one of the participating centres, will be asked to fill out a set of questionnaires (baseline questionnaire, health care utilization, decision making, EORTC QLQ-C30, DTF-specific questionnaire, and the EQ-5D-5L). Patients will only have to fill out these questionnaires once. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04289077
Study type	Observational
Source	Erasmus Medical Center
Contact
Status	Completed
Phase
Start date	August 6, 2020
Completion date	February 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05561036` - A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor	Phase 3
Completed	`NCT00287846` - Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis	Phase 1/Phase 2
Recruiting	`NCT06258421` - Burden of Disease and Living Situation in Desmoid Patients
Completed	`NCT00030680` - Radiation Therapy in Treating Patients With Aggressive Fibromatoses	Phase 2
Recruiting	`NCT06081400` - Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting	N/A
Active, not recruiting	`NCT04871282` - A Study of AL102 in Patients With Progressing Desmoid Tumors	Phase 2/Phase 3
Recruiting	`NCT01567046` - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas	N/A
Completed	`NCT01137916` - Study to Evaluate Imatinib in Desmoid Tumors	Phase 2
Completed	`NCT00002595` - Toremifene in Treating Patients With Desmoid Tumors	Phase 2
Completed	`NCT03459469` - Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059	Phase 1
Completed	`NCT06195085` - CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
Completed	`NCT01286662` - A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome	N/A
Completed	`NCT01265030` - A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	Phase 1/Phase 2
Completed	`NCT00068419` - Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor	Phase 2
Completed	`NCT03190174` - Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers	Phase 1/Phase 2
Completed	`NCT00003019` - Vinblastine and Methotrexate in Treating Children With Desmoid Tumors	Phase 2
Recruiting	`NCT05949099` - Study of Cryoablation and Nirogacestat for Desmoid Tumor	Phase 2
Active, not recruiting	`NCT02076906` - MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors	Phase 1
Completed	`NCT00474994` - Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas	Phase 2
Active, not recruiting	`NCT03785964` - Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Quality of Life of Patients With Desmoid-type Fibromatosis — QUALIFIED

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms